The future of induced proximity therapeutics.

Tim Shannon, MD, is CEO at Quarry Thera. He served as the founding CEO and then Chairman of Arvinas and Halda through their IPO (Arvinas) and acquisition (Halda). He has also served as an early investor and director of other successful companies, including Civitas, Novira, NextCure, CytomX, and IDEAYA. Other active companies where he is a director include Normunity, AER, Acesion, Triton, and Land. Prior to joining Canaan, he served as President and Chief Executive Officer of CuraGen, a publicly traded oncology-focused biopharmaceutical company. Before that, he was SVP of worldwide clinical development at Bayer. Earlier in his career, he was an Assistant Professor of Pulmonary and Critical Care Medicine at Yale. Tim earned his MD from the University of Connecticut and holds a BA in Chemistry from Amherst College.

Mikael Dolsten, M.D., Ph.D., is Co-founder and Executive Chairman of the Board of Quarry Thera. He previously served as Chief Scientific Officer and President of Worldwide Research, Development and Medical at Pfizer, where he led a global organization of more than 8,000 scientists advancing medicines across six therapeutic areas. During his tenure, Pfizer selected more than 150 drug candidates and achieved over 35 regulatory approvals, including numerous first-in-class and novel therapies spanning immunology, oncology, vaccines, and cardiovascular disease. Mikael brings more than 25 years of leadership experience in pharmaceutical research and development. He earned his medical degree and PhD from Lund University in Sweden, where he also served as Adjunct Professor of Tumor Immunology, and has authored more than 160 scientific publications. Mikael currently serves as a Board Director for several public life science companies, including Agilent, Apellis, and Rocket Pharma. He also works with private biotech firms such as ChAi Discovery, Enveda Bio, Orbis Medicine, ImmuneAI, BenchSci, and Arbor, while providing advisory services to business groups like Blackstone, Bain & Co, Samsung, GV, Canaan, and Formation Bio.

Craig Crews, Ph.D., is Co-Founder of Quarry Thera and the John C. Malone Professor of Molecular, Cellular and Developmental Biology at Yale University, with joint appointments in Chemistry and Pharmacology. He is widely recognized as a pioneer of targeted protein degradation and proximity-based therapeutics, having helped establish the scientific foundation for using small molecules to control intracellular protein levels. His work has led to the creation of several biotechnology companies, including Arvinas, Halda, and Proteolix. Research originating from Proteolix contributed to the discovery of carfilzomib (Kyprolis), an FDA-approved therapy for multiple myeloma. Dr. Crews has received numerous international honors for his contributions to chemical biology and drug discovery. He earned his BA in Chemistry from the University of Virginia and his PhD in Biochemistry from Harvard University.

Jeanne Magram, Ph.D., is Chief Scientific Officer at Quarry Thera, where she leads scientific strategy and advancement of the company’s proximity-induced therapeutics platform. She brings more than 25 years of experience advancing innovative medicines from discovery through early clinical development across biotech and global pharma. She previously served as Chief Scientific Officer at Celsius Therapeutics (acquired by AbbVie) and Northern Biologics, and earlier led immunology and inflammation research at Boehringer Ingelheim, delivering multiple candidates into preclinical and clinical development, including the approved therapy SKYRIZI. Earlier in her career, she held leadership roles at Pfizer and Roche focused on translating cutting-edge biology into differentiated therapeutics. Jeanne earned her PhD from Columbia University and completed her postdoctoral training in the laboratory of Nobel Laureate J. Michael Bishop.

Kanak Raina, Ph.D., is Chief Technology Officer at Quarry Thera, where he leads discovery strategy and execution across the company’s induced proximity portfolio. He brings more than a decade of experience in small-molecule drug discovery, with deep expertise in proximity-based technologies as an early team member at Arvinas and Halda. At Halda, he conceptualized the RIPTAC platform and led its proof-of-concept efforts, advancing the prostate cancer program from inception through IND clearance. Kanak earned his PhD in the Craig Crews Lab at Yale University.

Sean Cassidy is Chief Financial Officer of Quarry Thera, where he leads the company’s financial strategy and operations. He brings more than 20 years of experience in the life sciences industry across biotechnology and emerging therapeutics companies. Prior to joining Quarry, Sean served as Chief Financial Officer of Arvinas, a leader in targeted protein degradation, where he helped guide the company through significant growth and advancement of its clinical pipeline. Earlier in his career, he held CFO roles at Axerion Therapeutics and CuraGen Corporation and served as Director and Controller at 454 Life Sciences, a pioneer in next-generation DNA sequencing. Sean began his career at Deloitte advising healthcare and life sciences companies. He holds an MBA and BS from the University of Connecticut and is a Certified Public Accountant.

Jesús R. Medina, Ph.D., is a medicinal chemist with over 20 years of experience in drug discovery, with deep expertise in oncology research and targeted protein degradation. He spent six years at Arvinas, where he advanced PROTAC-based programs across Oncology and Immuno-Oncology, leading efforts from target selection through candidate nomination and contributing to two clinical candidates, including a selective KRAS G12D degrader now in Phase 1 trials. Earlier at GlaxoSmithKline, he led chemistry efforts across oncology programs and served as Operations and Science Leader for a Phase 1/2 study. Jesús earned his PhD from the University of Puerto Rico and completed postdoctoral training at the University of California, Berkeley.

Mikael Dolsten, M.D., Ph.D., is Co-founder and Executive Chairman of the Board of Quarry Thera. He previously served as Chief Scientific Officer and President of Worldwide Research, Development and Medical at Pfizer, where he led a global organization of more than 8,000 scientists advancing medicines across six therapeutic areas. During his tenure, Pfizer selected more than 150 drug candidates and achieved over 35 regulatory approvals, including numerous first-in-class and novel therapies spanning immunology, oncology, vaccines, and cardiovascular disease. Mikael brings more than 25 years of leadership experience in pharmaceutical research and development. He earned his medical degree and PhD from Lund University in Sweden, where he also served as Adjunct Professor of Tumor Immunology, and has authored more than 160 scientific publications. Mikael currently serves as a Board Director for several public life science companies, including Agilent, Apellis, and Rocket Pharma. He also works with private biotech firms such as ChAi Discovery, Enveda Bio, Orbis Medicine, ImmuneAI, BenchSci, and Arbor, while providing advisory services to business groups like Blackstone, Bain & Co, Samsung, GV, Canaan, and Formation Bio.

Craig Crews, Ph.D., is Co-Founder of Quarry Thera and the John C. Malone Professor of Molecular, Cellular and Developmental Biology at Yale University, with joint appointments in Chemistry and Pharmacology. He is widely recognized as a pioneer of targeted protein degradation and proximity-based therapeutics, having helped establish the scientific foundation for using small molecules to control intracellular protein levels. His work has led to the creation of several biotechnology companies, including Arvinas, Halda, and Proteolix. Research originating from Proteolix contributed to the discovery of carfilzomib (Kyprolis), an FDA-approved therapy for multiple myeloma. Dr. Crews has received numerous international honors for his contributions to chemical biology and drug discovery. He earned his BA in Chemistry from the University of Virginia and his PhD in Biochemistry from Harvard University.

Tim Shannon, MD, is CEO at Quarry Thera. He served as the founding CEO and then Chairman of Arvinas and Halda through their IPO (Arvinas) and acquisition (Halda). He has also served as an early investor and director of other successful companies, including Civitas, Novira, NextCure, CytomX, and IDEAYA. Other active companies where he is a director include Normunity, AER, Acesion, Triton, and Land. Prior to joining Canaan, he served as President and Chief Executive Officer of CuraGen, a publicly traded oncology-focused biopharmaceutical company. Before that, he was SVP of worldwide clinical development at Bayer. Earlier in his career, he was an Assistant Professor of Pulmonary and Critical Care Medicine at Yale. Tim earned his MD from the University of Connecticut and holds a BA in Chemistry from Amherst College.

Stephen Knight, MD, is President and Senior Managing Partner at F-Prime Capital, where he invests broadly across healthcare and life sciences. He brings more than 30 years of experience in biotechnology and pharmaceuticals and has helped build and guide numerous leading companies in the sector. Steve currently serves on the boards of Atalanta Therapeutics, Leyden Labs, Paradigm, Quarry Thera, and Xaira Therapeutics, and previously served on the boards of many companies, including Beam Therapeutics, Blueprint Medicines, Ultragenyx and Denali Therapeutics. He earned his MD and MBA from Yale University and a BS in Biology from Columbia University.

Dan leads the investment team at Yosemite, where he oversees the firm’s investments in therapeutics and digital health companies in the oncology space. Prior to helping launch Yosemite, Dan spent seven years at Emerson Collective, where he led the team’s cancer-focused investment efforts. He has held several biotech operating roles, including serving as interim CEO of Tune Therapeutics, a clinical-stage epigenetic editing company. Earlier in his career, Dan worked with biotech and private equity clients at Bain & Company. He holds a B.S. in Bioengineering and an M.S. in Management Science & Engineering from Stanford University.